Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 30, 2023

CHMP recommends approval of Bristol Myers Squibb’s Reblozyl

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Bristol Myers Squibb’s Reblozyl (luspatercept) for adult patients with anemia associated with non‑transfusion-dependent (NTD) beta thalassemia.

A giemsa stained blood smear from a person with beta thalassemia. Credit: Dr Graham Beards / commons.wikimedia.org.